Shadi Tabibian: Navigating Modern Diagnosis and Individualized Care in Hemophilia A and B
Shadi Tabibian, Deputy of research at Blood Diseases Research Centers in Iran University of Medical Sciences, shared a post on LinkedIn about a recent article by Ming Y. Lim et al, published in Journal of Thrombosis and Haemostasis, adding:
“Hemophilia A and B: From Diagnosis to Personalized Lifelong Care.
The management of hemophilia has evolved dramatically—from conventional factor replacement to extended half-life concentrates, FVIII mimetics, rebalancing agents, and gene therapy.
This recent educational review provides a comprehensive overview of:
- The genetic and pathophysiological basis of hemophilia A and B
- Clinical presentation and laboratory diagnosis
- The expanding treatment landscape
- Treatment monitoring and inhibitor management
- Hemophilic arthropathy and age-related comorbidities
- The essential role of multidisciplinary and personalized care
Despite major therapeutic advances, important challenges remain.
Inhibitor development, progressive joint disease, laboratory monitoring of novel therapies, equitable treatment access, and the growing burden of cardiovascular and other age-related conditions continue to shape clinical practice.
The key message is clear: modern hemophilia care must extend beyond bleeding control.
It should aim to preserve joint health, reduce treatment burden, improve quality of life, and support individuals with hemophilia throughout their lifespan.”
Title: Diagnosis and management of hemophilia A and B
Authors: Ming Y. Lim, Jesús Ardila, Giancarlo Castaman, Yesim Dargaud, Karin Fijnvandraat, Roberta Gualtierotti, Cedric Hermans, Susan Shapiro
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 25, 2026, 15:56Wolfgang Miesbach: Building the Future of Gene Therapy – From Centre Readiness to Long-Term Patient Care
-
Jun 25, 2026, 15:46Amber Yates: Making a Meaningful Difference for People Living with Sickle Cell Disease
-
Jun 25, 2026, 15:43Nancy Cavey: Navigating Disability Benefits for Patients with Immune Thrombocytopenia
-
Jun 25, 2026, 15:28Damon Race: Pursuing Long-Term Expression in Hemophilia A Gene Therapy
-
Jun 25, 2026, 15:23Jonas Kingo: ISTH 2026 in Paris Brings the Global Hemostasis Community Together
-
Jun 25, 2026, 15:21Balancing Therapeutic Progress and Emergency Preparedness in Hemophilia – CRH French Reference Center for Hemophilia Lyon
-
Jun 25, 2026, 15:06Ifeanyichukwu Ifechidere: What If One of the Biggest Myth Fact About APS is Hidden in its Name?
-
Jun 25, 2026, 15:05Gopal Patidar: Advancing Haemovigilance and Global Collaboration at ISBT 2026
-
Jun 25, 2026, 14:52Violeta Jardin: Measuring Antifibrinolytic Effect to Improve Tranexamic Acid Safety